The world's scientific and social network for malaria professionals
Subscribe to free Newsletter | 11146 malaria professionals are enjoying the free benefits of MalariaWorld today


Practices of anti-malaria pharmaceuticals inventory control system and associated challenges in public health facilities of Oromiya special zone, Amhara region, Ethiopia

November 10, 2021 - 20:54 -- Open Access
Mengesha HY, Gebrehiwot GM, Workneh BD, Kahissay MH
BMC Public Health. 2021 Nov 6;21(1):2026

Anti-malaria pharmaceuticals inventory control system helps to maintain an appropriate stock level using logistics management information system records and reports. Antimalaria pharmaceuticals are highly influenced by seasonality and demand variation. Thus, to compensate the seasonality, resupply quantities should be adjusted by multiplying the historical consumption with the Look-ahead seasonality indexes (LSI) to minimize stock-outs during the peak transmission season and overstocks (possible expiries) during off-peak seasons The purpose of this study was to assess anti-malaria pharmaceuticals inventory control practice and associated challenges in public health facilities of the Oromiya special zone, Amhara region, Ethiopia.

NOT Open Access | Integrating network pharmacology and experimental models to investigate the mechanisms of dihydroartemisinin in preventing NSCLC progression via mTOR/HIF-1α signaling

August 17, 2021 - 14:18 -- NOT Open Access
Li Y, Xiao X, Wang H, Zhou Q, Jin Z, Zhang Y, Wang Y, Yue F, Zhou S, Yang J
Eur J Pharmacol. 2021 Aug 11:174411

Advanced Non-small cell lung cancer (NSCLC) is the most common type of lung cancer with a poor prognosis. The anti-malaria compounds dihydroartemisinin (DHA) have shown to regulate multiple targets and signaling pathways in cancers, but a global view of its mechanism of action remains elusive. In present study, we integrated network pharmacology and in vitro and in vivo experimental models to investigate the mechanisms of DHA in preventing NSCLC proliferation.

Is biological larviciding against malaria a starting point for integrated multi-disease control? Observations from a cluster randomized trial in rural Burkina Faso

June 22, 2021 - 14:22 -- Open Access
Dambach P, Bärnighausen T, Yadouleton A, Dambach M, Traoré I, Korir P, Ouedraogo S, Nikiema M, Sauerborn R, Becker N, Louis VR
PLoS One. 2021 Jun 18;16(6):e0253597

To evaluate the impact of anti-malaria biological larviciding with Bacillus thuringiensis israelensis on non-primary target mosquito species in a rural African setting.

Advances in the research on the targets of anti-malaria actions of artemisinin

December 2, 2020 - 09:43 -- Open Access
Yang J, He Y, Li Y, Zhang X, Wong YK, Shen S, Zhong T, Zhang J, Liu Q, Wang J
Pharmacol Ther. 2020 Dec;216:107697

Malaria has been a global epidemic health threat since ancient times. It still claims roughly half a million lives every year in this century. Artemisinin and its derivatives, are frontline antimalarial drugs known for their efficacy and low toxicity. After decades of wide use, artemisinins remain our bulwark against malaria. Here, we review decades of efforts that aim to understand the mechanism of action (MOA) of artemisinins, which help explain the specificity and potency of this anti-malarial drug.

Chloroquine and Hydroxychloroquine in the Treatment of Malaria and Repurposing in Treating COVID-19

September 15, 2020 - 14:44 -- Open Access
Lei ZN, Wu ZX, Dong S, Yang DH, Zhang L, Ke Z, Zou C, Chen ZS
Pharmacol Ther. 2020 Sep 7:107672

Chloroquine (CQ) and Hydroxychloroquine (HCQ) have been commonly used for the treatment and prevention of malaria, and the treatment of autoimmune diseases for several decades. As their new mechanisms of actions are identified in recent years, CQ and HCQ have wider therapeutic applications, one of which is to treat viral infectious diseases.

ITEM-THREE analysis of a monoclonal anti-malaria antibody reveals its assembled epitope on the pfMSP119 antigen

September 1, 2020 - 10:05 -- Open Access
Opuni KFM, Koy C, Russ M, Reepmeyer M, Danquah BD, Weresow M, Alef A, Lorenz P, Thiesen HJ, Glocker MO
J Biol Chem. 2020 Aug 26:jbc.RA120.014802

Rapid diagnostic tests are first line assays for diagnosing infectious diseases, such as malaria. To minimize false positive and false negative test results in population screening assays, high quality reagents and well characterized antigens and antibodies are needed. An important property of antigen - antibody binding is recognition specificity which best can be estimated by mapping an antibody's epitope on the respective antigen.

Stocking pattern for anti-malarial medications among proprietary patent medicine vendors in Akinyele Local Government Area, Ibadan, Nigeria

August 4, 2020 - 16:12 -- Open Access
Mary Y. Kodaolu, Adeniyi F. Fagbamigbe and IkeOluwapo O. Ajayi
Malaria Journal 2020 19:279, 3 August 2020

Policymakers have recognized that proprietary patent medicine vendors (PPMVs) can provide an opportunity for effective scaling up of artemisinin-based combination therapy (ACT) since they constitute a major source of malaria treatment in Nigeria. This study was designed to determine the stocking pattern for anti-malarial medications, knowledge of the recommended anti-malarial medicine among PPMVs in Akinyele Local Government Area (LGA) of Oyo State, Nigeria and their perception on ways to improve PPMV adherence to stocking ACT medicines.

NOT Open Access | Gaps between Knowledge and Malaria Treatment Practices after Intensive Anti-Malaria Campaigns in Western Kenya: 2004-2016

March 23, 2020 - 14:08 -- NOT Open Access
Zhou G, Hemming-Schroeder E, Gesuge M, Afrane YA, Lee MC, Atieli HE, Githeko AK, Yan G
Am J Trop Med Hyg. 2020 Mar 16

Effective case management is central for malaria control, but not all of those affected by malaria have access to prompt, effective treatment. In Kenya, free malaria treatment has been implemented since 2006. However, questions remain regarding effective treatment. We conducted cross-sectional epidemiological and questionnaire surveys in four counties in western Kenya in 2004, 2010, and 2016, and antimalarial availability surveys in 2016.

NOT Open Access | Anti-tuberculosis activity of the anti-malaria cytochrome bcc oxidase inhibitor SCR0911

March 2, 2020 - 14:14 -- NOT Open Access
Chong S, Manimekalai MSS, Sarathy JP, Williams ZC, Harold LK, Cook GM, Dick T, Pethe K, Bates RW, Grüber G
ACS Infect Dis. 2020 Feb 24

The ability to respire and generate ATP is essential for the physiology, persistence and pathogenicity of Mycobacterium tuberculosis, which causes Tuberculosis. By employing a lead repurposing strategy, the malarial cytochrome bc1 inhibitor SCR0911 was tested against mycobacteria. Docking studies were carried out to reveal potential binding and to understand the binding interactions with the target, cytochrome bcc.


Subscribe to RSS - anti-malaria